Stock vs Stock Comparison

AbbVie Inc. vs Eli Lilly and Company

LLY wins the Tale of the Tape 6–2.

ABBV$215.40
LLY$1064.15

🏆 Tale of the Tape

26
ABBVLLY
6.9%Profitability (Net Margin)31.7%
106.2xValuation (P/E)39.2x
8.3%Efficiency (ROIC)30.4%
7/9Health (Piotroski F)7/9
2.0Safety (Altman Z)7.8
8.6%Growth (Rev YoY)44.7%
0.61Risk (Sharpe 1Y)0.61
-42.50xBalance Sheet (D/E)3.24x
4.23%FCF Yield0.68%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.359
252-Day Correlation
0.243
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricABBVLLY
Market Cap$384.7B$985.4B
P/E Ratio106.2x39.2x
Forward P/E13.4x24.8x
P/B-57.80x31.65x
Dividend Yield3.18%0.63%
Beta0.300.48

Quantitative Metrics

MetricABBVLLY
DCF Fair Value$126.26$296.11
DCF Upside-38.9%-68.2%
Piotroski F7/97/9
Altman Z2.017.84
Beneish M-2.87-1.91
FCF Yield4.23%0.68%
Net Debt/EBITDA3.0x1.1x
ROIC8.3%30.4%
WACC7.4%7.8%
ROIC – WACC0.8pp22.5pp
Gross Margin70.2%83.0%
Net Margin6.9%31.7%
Rev Growth YoY8.6%44.7%
Sharpe (1Y)0.610.61
Max Drawdown 3Y
FCF Payout Ratio65%90%

ABBV Price

Loading chart...

LLY Price

Loading chart...

ETF Exposure

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

LLY found in:

XLV15.40%
IYH13.72%
VHT12.15%
VIG3.33%
SCHG3.17%
QUAL2.92%
MGK2.82%
IWF2.66%
VONG2.42%
SPYG2.36%
VUG2.31%
IVW2.23%
QUS1.95%
XPH1.90%
ESGV1.48%
DGRW1.46%
IVV1.46%
SCHX1.34%
SPY1.29%
ITOT1.29%
SCHB1.25%
VFQY1.23%
VOO1.20%
SPTM1.20%
VTI1.14%
VONE1.14%
SPLG1.10%
ARKG1.04%
URTH0.99%
ACWI0.87%
VT0.66%
VFMO0.46%
RSP0.20%
ONEO0.02%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

ABBV vs LLY: Head-to-Head Analysis

AbbVie Inc. (ABBV) and Eli Lilly and Company (LLY) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, LLY leads 6–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, ABBV generates a return on invested capital (ROIC) of 8.3% compared to LLY's 30.4%. This suggests LLY is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between ABBV and LLY is 0.359, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

ABBV appears in 38 ETFs tracked by SecuritiesDB, while LLY appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, ABBV or LLY?

Our quantitative analysis compares ABBV and LLY across nine fundamental dimensions. LLY wins the Tale of the Tape 6–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are ABBV and LLY correlated?

The 252-day correlation between ABBV and LLY is 0.359. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.